Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | IAPP | P10997 | 2/20 | 0.38 |
| ▸ | OXER1 | Q8TDS5 | 6/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004060 | 1.00 | TRPA1 (0.45) | TRPA1KDM4EIAPPOXER1ALOX12 | |
| SCHEMBL3007779 | 1.00 | TRPA1 (0.45) | TRPA1KDM4EIAPPOXER1ALOX12 | |
| SCHEMBL19743405 | 0.84 | TRPA1 (0.59) | TRPA1KDM4EIAPPOXER1ALOX12 | |
| SCHEMBL430423 | 0.84 | TRPA1 (0.63) | TRPA1KDM4EOXER1ALOX12CES2 | |
| SCHEMBL430424 | 0.84 | TRPA1 (0.63) | TRPA1KDM4EOXER1ALOX12CES2 | |
| SCHEMBL13611745 | 0.81 | ALDH1A1 (0.40) | TRPA1KDM4EIAPPOXER1CNR1 | |
| SCHEMBL13611712 | 0.81 | ALDH1A1 (0.40) | TRPA1KDM4EIAPPOXER1CNR1 | |
| SCHEMBL7747547 | 0.81 | TRPA1 (0.39) | TRPA1KDM4EOXER1ALOX12CNR1 | |
| SCHEMBL13953154 | 0.81 | ALDH1A1 (0.40) | TRPA1KDM4EIAPPOXER1CNR1 | |
| SCHEMBL6941507 | 0.81 | KDM4E (0.51) | TRPA1KDM4EOXER1ALOX12CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2178399-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009009916-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | OR10J3, ALOX5, OR51E2 | TRPA1 6/4885KDM4E 4306/4885IAPP 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.